TIDMERGO
RNS Number : 1029S
Ergomed plc
28 September 2017
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN, IS NOT
FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY,
IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA,
AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF IRELAND OR THE REPUBLIC
OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE
UNLAWFUL TO DO SO.
Ergomed plc
Result of Placing
London, UK - 28 September 2017: Ergomed plc (AIM: ERGO)
("Ergomed" or the "Company"), a specialised pharmaceutical services
and drug development company, is pleased to announce the result of
the placing announced earlier today (the "Placing").
A total of 1,757,576 new ordinary shares in the Company of 1p
each (the "Placing Shares") have been conditionally placed at a
price of 165p per Placing Share (the "Placing Price"), raising
proceeds of GBP2.9m (before expenses) to part-fund the acquisition
of PSR Group BV.
The Placing Shares to be issued represent approximately 4.3% of
the Company's existing issued ordinary share capital. The Placing
Price represents a discount of approximately 4.1% to the Company's
last 30 trading days volume weighted average price.
Numis Securities Limited ("Numis") and N+1 Singer Advisory LLP
("N+1 Singer") have acted as joint bookrunners in respect of the
Placing. Other than where defined, capitalised terms used in this
announcement have the meanings given to them in the announcement
released by the Company this morning at 7.00 a.m.
Director participation
The participation of Directors of Ergomed who have taken up
Placing Shares at the Placing Price is as follows:
Director Interest Aggregate Number Interest Resulting
in value of Ordinary in Ordinary holding
Ordinary of Ordinary Shares Shares of Ordinary
Shares Shares to be following Shares as
to be acquired the % of enlarged
acquired Placing issued share
(GBP) capital
-------------- ---------- ------------- ------------- ------------- ---------------
Peter George 231,250 74,250.00 45,000 276,250 0.65%
-------------- ---------- ------------- ------------- ------------- ---------------
Admission
Application has been made to the London Stock Exchange for the
Placing Shares to be admitted to trading on AIM ("Admission"). It
is currently expected that settlement of all of the Placing Shares
and Admission will take place at 8.00 a.m. on or around 2 October
2017. The Placing is conditional upon, inter alia, Admission
becoming effective and the Placing Agreement becoming unconditional
and not being terminated in accordance with its terms.
Total voting rights
Following Admission the number of ordinary shares of 1 penny
each in the capital of the Company in issue and number of voting
rights will be 42,680,813. The above figure may be used by
Shareholders as the denominator for the calculations by which they
will determine whether they are required to notify their interest
in, or a change to their interest in, the Company under the
Financial Conduct Authority's Disclosure and Transparency
Rules.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial
responsibilities/person closely associated
---- -------------------------------------------------------------
a) Name Peter George
---- ------------------------- ----------------------------------
2 Reason for the notification
---- -------------------------------------------------------------
a) Position/status Chairman
---- ------------------------- ----------------------------------
b) Initial Initial Notification
notification
/Amendment
---- ------------------------- ----------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
---- -------------------------------------------------------------
a) Name Ergomed Plc
---- ------------------------- ----------------------------------
b) Legal Entity 213800BVS8I9VMC1AP84
Identifier
---- ------------------------- ----------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
---- -------------------------------------------------------------
a) Description Ordinary shares of 1 pence each
of the
financial
instrument, GB00BN7ZCY67
type of
instrument
Identification
code
---- ------------------------- ----------------------------------
b) Nature Purchase of shares
of the
transaction
---- ------------------------- ----------------------------------
c) Currency GBP
---- ------------------------- ----------------------------------
d) Price(s) Price(s) Volume(s)
and volume(s)
---- ------------------------- ---------------- ----------------
165p 45,000
------------------------------ ---------------- ----------------
e) Aggregated
information
- Aggregated
volume
- Price 45,000
- Aggregated 165p
total
GBP74,250.00
------------------------------ ----------------------------------
f) Date of 28 September 2017
the transaction
---- ------------------------- ----------------------------------
g) Place of London Stock Exchange, AIM
the transaction
---- ------------------------- ----------------------------------
Enquiries:
Ergomed plc Tel: +44 (0)
1483 503205
Dan Weng (Chief Executive Officer)
Stephen Stamp (Chief Financial
Officer)
Numis Securities Limited Tel: +44 (0)
20 7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black (Joint Broker)
N+1 Singer Tel: +44 (0)
20 7496 3000
Alex Price (Joint Broker)
Michael Taylor
Consilium Strategic Communications Tel: +44 (0)
- for UK enquiries 20 3709 5700
Chris Gardner / Mary-Jane ergomed@consilium-comms.com
Elliott
Ivar Milligan / Philippa Gardner
MC Services - for Continental Tel: +49 211
European enquiries 5292 5222
Anne Hennecke
About Ergomed
Ergomed provides specialist services to the pharmaceutical
industry and develops drugs both wholly-owned and through
partnerships. Ergomed's fast-growing, profitable service offering
spans all phases of clinical development and post-approval
pharmacovigilance and medical information. Drawing on more than 20
years of expertise in drug development, Ergomed is also building a
growing portfolio of drug development partnerships and programmes,
including wholly-owned proprietary products for the treatment of
surgical bleeding. For further information, visit:
http://ergomedplc.com
About PSR
PSR, established in 1998, is a full service specialist orphan
drug CRO and recognised as a leading expert in the rare disease
niche. PSR specialises in running complex orphan drug development
programs requiring innovative regulatory and clinical approaches as
well as pricing and reimbursement strategies. Besides outsourced
project solutions, PSR provides insourced staffing solutions
(orphan drug teams), temporary & permanent staffing, interim
management solutions as well as training / coaching career
programs.
PSR's dedication to the rare disease landscape is exemplified by
an extensive track record of orphan drug projects in a wide range
of therapeutic areas, its continued efforts to achieve true patient
centricity and its societal commitments by participation in
fundraising activities and public-private partnerships. For
further
information, visit: http://www.psr-group.com.
This announcement contains inside information which is disclosed
in accordance with the Market Abuse Regulation.
Each of Numis Securities Limited and Nplus1 Singer Advisory LLP,
both of which are regulated in the UK by the Financial Conduct
Authority, is acting for the Company and no one else in connection
with the Placing, and will not be responsible to any person other
than the Company for providing the regulatory and legal protections
afforded to their respective clients nor for providing advice in
relation to the contents of this Announcement or any matter,
transaction or arrangement referred to in it.
This Announcement includes statements, estimates, opinions and
projections with respect to anticipated future performance of the
Company or future events ("forward-looking statements") which
reflect various assumptions concerning anticipated results or
events which may or may not prove to be correct. These forward
looking statements can be identified by the use of forward looking
terminology, including the terms "anticipates", "target",
"believes", "estimates", "expects", "intends", "may", "plans",
"projects", "should" or "will", or, in each case, their negative or
other variations or comparable terminology or by discussions of
strategy, plans, objectives, goals, future events or intentions.
Such forward-looking statements reflect current expectations based
on the current business plan and various other assumptions and
involve significant risks and uncertainties and should not be read
as guarantees of future performance or results and will not
necessarily be accurate indications of whether or not such results
will be achieved. As a result, prospective investors should not
rely on such forward-looking statements due to the inherent
uncertainty therein. No representation or warranty is given as to
the completeness or accuracy of the forward-looking statements
contained in this Announcement. Forward-looking statements speak
only as of the date of such statements and, except as required by
the FCA, the London Stock Exchange or applicable law, the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise. No statement in this Announcement is
intended to be a profit forecast and no statement in this
Announcement should be interpreted to mean that earnings per share
of the Company for the current or future financial years would
necessarily match or exceed the historical published earnings per
share of the Company. The price of shares and the income from them
may go down as well as up and investors may not get back the full
amount invested on disposal of the Placing Shares.
The distribution of this Announcement and the offering of the
Placing Shares in certain jurisdictions may be restricted by law.
No action has been taken by the Company or the Bookrunners that
would permit an offering of the Placing Shares or possession or
distribution of this Announcement or any other offering or
publicity material relating to the Placing Shares in any
jurisdiction where action for that purpose is required. Persons
into whose possession this Announcement comes are required by the
Company and the Bookrunners to inform themselves about, and to
observe, such restrictions.
The Placing Shares to be issued pursuant to the Placing will not
be admitted to trading on any stock exchange other than the London
Stock Exchange.
Neither the content of the Company's website nor any website
accessible by hyperlinks on the Company's website is incorporated
in, or forms part of, this Announcement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROIPGUCCBUPMUBR
(END) Dow Jones Newswires
September 28, 2017 05:46 ET (09:46 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024